Medroxyprogesterone Acetate

• CAT Number: A000995
• CAS Number: 71-58-9
• Molecular Formula: C24H34O4
• Molecular Weight: 386.52
• Purity: ≥95%
• Synonyms: 71-58-9; Medroxyprogesterone 17-acetate; Metigestrona; Provera; Depo-Provera
• Target: Immunology/Inflammation
• Solubility: Soluble in DMSO > 10 mM
• Storage: -20°C
• IUPAC Name: [(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
• InChI: InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1
• InChIKey: PSGAAPLEWMOORI-PEINSRQWSA-N
• SMILES: C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C

Medroxyprogesterone acetate (Cat No.:A000995) is a synthetic progestin, derived from progesterone, widely used in hormonal therapies and contraceptives. It is most commonly administered as an oral tablet or long-acting intramuscular injection (Depo-Provera) for birth control, treatment of endometriosis, abnormal uterine bleeding, and menopausal symptoms. MPA binds to progesterone receptors, exerting anti-estrogenic effects on the endometrium and inhibiting ovulation. It is also used in hormone replacement therapy and certain hormone-sensitive cancers like endometrial or breast cancer. MPA is valued for its long duration of action, high potency, and clinical versatility.